The Suédo-British Laboratory Astrazeneca announced, this Thursday, March 25, 2021, that its coronavirus vaccine is 76% effective against symptomatic cases.
The laboratory thus revives the effectiveness rate of its vaccine estimated at the start at 79%.
The results of the “primary analysis of phase III tests (of the vaccine) in the United States confirmed that (sound) efficiency was consistent” with the data announced on Monday, Astrazeneca said in a press release.
The laboratory also announced that the efficiency of its vaccine was 100 % to prevent serious cases of COVID-19, a figure similar to that announced above, reports AFP.
This vaccine faces enormous criticism and even accusations given certain adverse effects. Used in many countries including the European Union, the vaccine developed by Astrazeneca and the University of Oxford has not yet been approved in the United States.
Tunisia has already ordered doses of this vaccine, but according to the director of the Pasteur Institute of Tunis, these orders could be canceled in the event of confirmation of these cases of undesirable effects.
